Farber disease: Understanding a fatal childhood disorder and dissecting ceramide biology

EMBO Molecular Medicine

Volumn 5, Issue 6, 2013, Pages 799-801

  Sands, Mark S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acid ceramidase; Ceramide; Farber disease; Lysosomal storage disease

Indexed keywords

ACID CERAMIDASE; CERAMIDE; GALACTOSYLCERAMIDE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; LENTIVIRUS VECTOR; LYSOSOME ENZYME; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT ENZYME; SPHINGOLIPID; SPHINGOMYELIN; TUMOR MARKER;

APOPTOSIS; ARTHROPATHY; ARTICLE; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CARCINOGENESIS; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME METABOLISM; ENZYME REPLACEMENT; EPIPHYSIS PLATE; FARBER DISEASE; GENE DELETION; GENE TARGETING; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; HEART DISEASE; HOARSENESS; HUMAN; HYDROCEPHALUS; JOINT STIFFNESS; LIPID METABOLISM; LIPID RAFT; LUNG DISEASE; MISSENSE MUTATION; NEWBORN DEATH; NONHUMAN; OVARY DEVELOPMENT; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUBCUTANEOUS NODULE;

ANIMALS; CERAMIDES; FARBER LIPOGRANULOMATOSIS; FEMALE; HUMANS;

EID: 84878740987     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201302781     Document Type: Article

References (10)

1. Alayoubi AM, Wang JCM, Au BCY, Carpentier S, Garcia V, Dworski S, Ghamrasni SE, Kirouac KN, Exertier J, Xiong ZJ, et al (2013) Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med DOI: 10.1002/emmm.201202301
2. Bieberich E (2012) It's a lipid world: bioactive lipid metabolism and signaling in neural stem cell differentiation. Neurochem Res 37: 1208-1229
3. Eliyahu E, Shtraizent N, Shalgi R, Schuchman EH (2012) Construction of conditional ceramidase knockout mice and in vivo effects on oocyte development and fertility. Cell Physiol Biochem 30: 735-748
4. Farber S, Cohen J, Uzman LL (1957) Lipogranulomatosis: a new lipo-glyco-protein "storage" disease. J Mt Sinai Hosp 24: 816-837
5. Hawkins-Salsbury JA, Reddy AS, Sands MS (2011) Combination therapy for lysosomal storage diseases: is the whole greater than the sum of its parts? Hum Mol Genet 20: R54- R60
6. Li CM, Park JH, He X, Levy B, Chen F, Arai K, Adler DA, Disteche CM, Koch J, Sandhoff K, et al (1999) The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. Genomics 62: 223-231
7. Li CM, Park JH, Simonaro CM, He X, Gordon RE, Friedman AH, Ehleiter D, Paris F, Manova K, Hepbildikler S, et al (2002) Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics 79: 218-224
8. Park JH, Schuchman EH (2006) Acid ceramidase and human disease. Biochim Biophys Acta 1758: 2133-2138
9. Sabourdy F, Kedjouar B, Sorli SC, Colie S, Milhas D, Salma Y, Levade T (2008) Functions of sphingolipid metabolism in mammals-lessons from genetic defects. Biochim Biophys Acta 1781: 145-183
10. Sands MS, Davidson BL (2006) Gene therapy for lysosomal storage diseases. Mol Ther 13: 839-849